SCHEDULE 13G 0001410830 XXXXXXXX LIVE Common Stock, $0.001 par value per share 03/31/2025 0001842295 Maze Therapeutics, Inc. 578784100 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(d) Matrix Capital Management Company, LP DE 0.00 2486184.00 0.00 2486184.00 2486184.00 N 5.7 IA PN David E. Goel X1 0.00 2486184.00 0.00 2486184.00 2486184.00 N 5.7 HC IN Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300, South San Francisco, CA 94080 This statement is filed by: Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to Matrix Capital Management Master Fund, LP (the "Matrix Fund"), with respect to the shares of common stock, $0.001 par value per share (the "Shares") of Maze Therapeutics, Inc. (the "Company") directly held by the Matrix Fund; and Mr. David E. Goel (the "Mr. Goel"), the Managing General Partner of the Investment Manager, with respect to the Shares directly held by the Matrix Fund. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons". The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein. The address of the business office of each of the Reporting Persons is Bay Colony Corporate Center, 1000 Winter Street, Suite 4500, Waltham, MA 02451. The Investment Manager is a Delaware limited partnership. Mr. Goel is a citizen of the United States. Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 43,796,057 Shares outstanding as of March 25, 2025, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 31, 2025. 5.7% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). The Matrix Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Shares. Y Y Y Y Exhibit 99.1: Joint Filing Agreement Matrix Capital Management Company, LP /s/ David E. Goel 05/14/2025 David E. Goel /s/ David E. Goel 05/14/2025